Data Provided by Refinitiv. Minimum 15 minutes delayed.

Immunovaccine Receives Final Approval to Graduate to TSX

November 24, 2014 at 12:00 AM EST

Halifax, Nova Scotia; November 24, 2014 — Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX Venture: IMV), a clinical stage vaccine and immunotherapy company, today announced it has received final approval from Toronto Stock Exchange (“TSX”) to graduate from TSX Venture Exchange and list its common shares (the “Common Shares”) on TSX. 

The Common Shares will commence trading on TSX effective as of the opening of markets on November 26, 2014. Upon listing on TSX, the Common Shares will continue to trade under the symbol “IMV”. In conjunction with the listing of the Common Shares on TSX, the Common Shares will be delisted from TSX Venture Exchange upon commencement of trading on TSX on November 26, 2014.

“We look forward to begin trading on TSX and the broader exposure that this exchange will provide Immunovaccine to investors in Canada and other key markets,” stated Dr. Marc Mansour, chief executive officer of Immunovaccine.  “With this TSX graduation and our significant cash reserves, which provide operating capital well into 2016, we find ourselves in a strong position to deliver scientifically and financially on our projects.”  

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Dr. Marc Mansour, Chief Executive Officer, Immunovaccine Inc.

T: (902) 492-1819 E:


Tim Brons, Vida Strategic Partners (media)

T: (415) 675-7402 E: